Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Nyheder Til nyhedsfeedet
Advanced Medical Solutions extends deadline for H.B. Fuller to 2 July
Advanced Medical Solutions has extended the “put up or shut up” deadline for H.B. Fuller to 2 July 2026 at 17:00 London time. The Takeover Panel approved the extension; the original deadline expired today. The parties continue to hold talks, no firm offer has been confirmed, and the AMS board is advising shareholders to take no action for now. » Mere på de.investing.com
Advanced Medical Solutions invites shareholders to annual general meeting on 17 June
Advanced Medical Solutions has sent its annual report and financial statements for the year ended 31 December 2025, together with the invitation to the annual general meeting, to shareholders. The AGM will be held on 17 June 2026 at 11:00 in the offices of Investec Bank, 30 Gresham Street, London. The annual report, financial statements and proxy form are available in the investor relations section of the company's website. » Mere på de.investing.com
Advanced Medical Solutions: 2025 annual results in line with guidance with strong Surgical growth
Advanced Medical Solutions reported 2025 revenue of £228.9m and adjusted EBITDA of £49.9m (adjusted EBITDA margin 21.8%), in line with the January update and analyst consensus. The Surgical division grew 36% at constant currency and was a major contributor; Woundcare rose 9% at constant currency. Margins were 24.4% (Surgical) and 13.6% (Woundcare); EPS came in 3% below the FactSet consensus due to higher interest expenses. Synergies from the acquisitions of Peters and Syntacoll are progressing as planned, and the company expects 2026 revenue and EBITDA to be in line with market expectations, with strong cash generation to reduce debt. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 134,02 mio. | - |
| Bruttofortjeneste | 64,69 mio. | - |
| Nettoresultat | -75,45 t | - |
| EBITDA | 30,16 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 732,72 mio. € |
Antal aktier | 216,4 mio. |
Højeste/laveste i 52 uger | 3,41 € - 2,24 € |
| Udbytte | Nej |
Beta | 0,75 |
P/E (PE Ratio) | 166,18 |
PEG (PEG Ratio) | -2,78 |
K/I (PB Ratio) | 2,41 |
P/S (PS Ratio) | 2,62 |
Virksomhedsprofil
Advanced Medical Solutions Group plc og dets datterselskaber designer, udvikler, fremstiller og distribuerer produkter til markederne for sårbehandling, kirurgi og sårlukning i Storbritannien, Tyskland, Frankrig, resten af Europa, USA og internationalt. Virksomheden er opdelt i to segmenter, Surgical og Woundcare. Segmentet Surgical tilbyder topiske vævslim til sårlukning og forsegling under mærket LiquiBand; suturer og kollagenbaserede produkter til kirurgiske og tandlægemarkeder under mærket RESORBA; kollagener; samt et laparoskopisk udstyr, der bruges til at fiksere hernienet placeret inde i kroppen under mærket LiquiBand Fix8, samt interne forseglingsmidler under mærkerne Seal-G/Seal-G MIST. Segmentet Woundcare leverer platformsteknologier til sårbehandling, herunder alginater, skum, film, fibre, hydrogeler, antimikrobielle forbindinger og hydrokolloider, samt produkter til sårbehandling under mærket ActivHeal. Advanced Medical Solutions Group plc blev stiftet i 1991 og har hovedkontor i Winsford, Storbritannien.
| Navn | Advanced Medical Solutions |
| CEO | Andrew Christopher Meredith |
| Hjemsted | Winsford,
ch Storbritannien |
| Websted | |
| Børsnotering | 16.12.1994 |
| Medarbejdere | 1.800 |
Tickersymboler
| Børs | Symbol |
|---|---|
London Stock Exchange | AMS.L |
Frankfurt | AQA.F |
Düsseldorf | AQA.DU |
London | AMS.L |